Boston Scientific touts increased HF risk detection in HeartLogic study

Boston Scientific (NYSE:BSX) today released new data from the MultiSense study of its HeartLogic heart failure diagnostic designed to predict heart failure decompensation, touting increased detection and classification of patients as high or low-risk for future HF events.

The HeartLogic diagnostic is designed to provide continuous monitoring of possible heart failure by combining sensors tracking heart sounds, respiration rate and volume, thoracic impedance, heart rate and activity, Marlborough, Mass.-based Boston Scientific said.

Results from the 900-patient MultiSense trial was presented at the Heart Failure Society of America’s 21st annual scientific meeting in Dallas.

Data from the trial indicated that the HeartLogic diagnostic was able to expand upon the ability of baseline blood tests to help identify patients at high risk for HF events, and the combination of the HeartLogic with a baseline NT-proBNP was able to accurately identify patients with risk groups at 23 to 50 times increased risk for such events.

“Through the utilization of the HeartLogic diagnostic, physicians can more accurately triage appropriate care to this vulnerable patient population in a timely manner, particularly when using the alert in combination with an intermittent measure of NT-proBNP,” principal investigator Dr. John Boehmer of the Penn State Health Milton S. Hershey Medical Center said in a prepared statement.

Previously published data on the HeartLogic system reported a 70% sensitivity and the ability to provide weeks of advance notice and low burden for detecting indications of worsening, Boston Scientific said.

“The data presented today further prove the value of the HeartLogic diagnostic in the early prediction of HF events. Our commitment to innovation in heart failure remains steadfast, and we look forward to the seeing continued results of the alert in a clinical setting,” global health policy & rhythm management chief medical officer Dr. Kenneth Stein said in a prepared release.

Yesterday, Boston Scientific released 3-year follow-up cohort results from the post-FDA approved PAS2 clinical trial of its Alair system designed for bronchial thermoplasty to treat severe persistent asthma, touting reduced severe asthma attacks, hospitalizations and ER visits.

The post Boston Scientific touts increased HF risk detection in HeartLogic study appeared first on MassDevice.

from MassDevice http://ift.tt/2hfifjM